(VIANEWS) – Highway Holdings Limited (HIHO), Helmerich & Payne (HP), Bristol (BMY) are the highest payout ratio stocks on this list.
We have collected information concerning stocks with the highest payout ratio at the moment. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. Highway Holdings Limited (HIHO)
227.27% Payout Ratio
Highway Holdings Limited, together with its subsidiaries, manufactures and supplies metal, plastic, electric, and electronic components, subassemblies, and finished products for original equipment manufacturers (OEMs) and contract manufacturers. It operates through two segments, Metal Stamping and Mechanical OEM; and Electric OEM. The company also trades in plastic injection products; and manufactures and assembles automation equipment. Its products are used in the manufacture of products, such as photocopiers, laser printers, print cartridges, electrical connectors, electrical circuits, vacuum cleaners, LED power supplies, stepping motors, pumps for dishwashers, and other washing machine components. In addition, the company assists customers in the design and development of the tooling used in the metal and plastic manufacturing process, as well as provides an array of other manufacturing and engineering services, including metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. It operates in Hong Kong and China, Europe, North America, and other Asian countries. Highway Holdings Limited was incorporated in 1990 and is headquartered in Sheung Shui, Hong Kong.
Earnings Per Share
As for profitability, Highway Holdings Limited has a trailing twelve months EPS of $0.11.
PE Ratio
Highway Holdings Limited has a trailing twelve months price to earnings ratio of 17.73. Meaning, the purchaser of the share is investing $17.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.75%.
2. Helmerich & Payne (HP)
86.36% Payout Ratio
Helmerich & Payne, Inc., together with its subsidiaries, provides drilling services and solutions for exploration and production companies. The company operates through three segments: North America Solutions, Offshore Gulf of Mexico, and International Solutions. The North America Solutions segment drills primarily in Colorado, Louisiana, Montana, Nevada, New Mexico, North Dakota, Ohio, Oklahoma, Pennsylvania, Texas, Utah, West Virginia, and Wyoming. The Offshore Gulf of Mexico segment has drilling operations in Louisiana and in U.S. federal waters in the Gulf of Mexico. The International Solutions segment conducts drilling operations in Argentina, Bahrain, Colombia, and the United Arab Emirates. As of September 30, 2022, the company operated a fleet of 236 land rigs in North America; 28 international land rigs; and 7 offshore platform rigs. It also focuses on developing, promoting, and commercializing technologies designed to enhance the drilling operations, as well as wellbore quality and placement. In addition, the company owns and operates commercial real estate properties. Its real estate investments include a shopping center comprising approximately 366,000 leasable square feet; and approximately 176 acres of undeveloped real estate located in Tulsa, Oklahoma. The company was founded in 1920 and is headquartered in Tulsa, Oklahoma.
Earnings Per Share
As for profitability, Helmerich & Payne has a trailing twelve months EPS of $1.43.
PE Ratio
Helmerich & Payne has a trailing twelve months price to earnings ratio of 26.17. Meaning, the purchaser of the share is investing $26.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.59%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Helmerich & Payne’s EBITDA is 23.75.
Revenue Growth
Year-on-year quarterly revenue growth grew by 75.6%, now sitting on 2.37B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 735.3% and 363%, respectively.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 16, 2023, the estimated forward annual dividend rate is 1.71 and the estimated forward annual dividend yield is 4.58%.
3. Bristol (BMY)
74.24% Payout Ratio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Bristol has a trailing twelve months EPS of $3.43.
PE Ratio
Bristol has a trailing twelve months price to earnings ratio of 19.87. Meaning, the purchaser of the share is investing $19.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.91%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 1.5% and 7.8%, respectively.
Yearly Top and Bottom Value
Bristol’s stock is valued at $68.17 at 02:23 EST, way under its 52-week high of $81.44 and above its 52-week low of $65.28.
Moving Average
Bristol’s value is below its 50-day moving average of $69.66 and under its 200-day moving average of $72.76.
Sales Growth
Bristol’s sales growth is negative 0.9% for the present quarter and 0.3% for the next.
Previous days news about Bristol (BMY)
- According to Zacks on Tuesday, 2 May, "Among the biotechs, Amgen and Bristol Myers beat estimates for earnings but missed on sales. "
4. National Oilwell Varco (NOV)
51.28% Payout Ratio
National Oilwell Varco, Inc. designs, constructs, manufactures, and sells systems, components, and products for oil and gas drilling and production worldwide. It operates through three segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. The company offers various equipment and technologies used to perform drilling operations. It also provides solids control and waste management equipment and services; drilling fluids; portable power generation products; drill and wired pipes; drilling optimization and automation services; tubular inspection, repair, and coating services; instrumentation, and measuring and monitoring services; downhole and fishing tools; steerable technologies; and drill bits. The company offers equipment and technologies for hydraulic fracture stimulation, including pressure pumping trucks, blenders, sanders, hydration units, injection units, flowline, and manifolds; well intervention, such as coiled tubing units, coiled tubing, and wireline units, as well as blowout preventers and tools; onshore production comprising fluid processing systems, composite pipes, surface transfer and progressive cavity pumps, and artificial lift systems; offshore production that include fluid processing systems, floating production systems, and subsea production technologies; and connectors for conductor pipes. It also provides substructures, derricks, and masts; cranes; jacking systems; pipe lifting, racking, rotating, and assembly systems; mud pumps; blowout preventers; drives and generators; rig instrumentation and control systems; equipment components for offshore wind construction vessels; mooring, anchor, and deck handling machinery; and pipelay and construction systems. The company offers spare parts, repair, and rentals, as well as remote equipment monitoring, technical support, field service, and customer training services. National Oilwell Varco, Inc. was founded in 1862 and is based in Houston, Texas.
Earnings Per Share
As for profitability, National Oilwell Varco has a trailing twelve months EPS of $0.39.
PE Ratio
National Oilwell Varco has a trailing twelve months price to earnings ratio of 48.26. Meaning, the purchaser of the share is investing $48.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.04%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 269.2% and 50%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
National Oilwell Varco’s EBITDA is 41.42.
5. Walker & Dunlop (WD)
37.74% Payout Ratio
Walker & Dunlop, Inc., through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products and services for owners and developers of real estate in the United States. The company offers first mortgage, second trust, supplemental, construction, mezzanine, preferred equity, small-balance, and bridge/interim loans. It also provides multifamily finance for manufactured housing communities, student housing, affordable housing, and senior housing properties under the Fannie Mae's DUS program; and construction and permanent loans to developers and owners of multifamily housing, affordable housing, senior housing, and healthcare facilities. In addition, the company acts as an intermediary in the placement of commercial real estate debt between institutional sources of capital, including life insurance companies, investment banks, commercial banks, pension funds, CMBS conduits, and other institutional investors, as well as owners of various types of commercial real estate. Further, it advises on capital structure; develops the financing package; facilitates negotiations between its client and institutional sources of capital; coordinates due diligence; and assists in closing the transaction. Additionally, the company offers property sales brokerage, underwriting and risk management, and servicing and asset management services. Walker & Dunlop, Inc. was founded in 1937 and is headquartered in Bethesda, Maryland.
Earnings Per Share
As for profitability, Walker & Dunlop has a trailing twelve months EPS of $6.36.
PE Ratio
Walker & Dunlop has a trailing twelve months price to earnings ratio of 11.36. Meaning, the purchaser of the share is investing $11.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.68%.
Volume
Today’s last reported volume for Walker & Dunlop is 186156 which is 5.75% above its average volume of 176019.
